透析療法ネクスト　XVIII

出版社： 医学図書出版
著者：
発行日： 2014-12-10
分野： 臨床医学：内科  >  腎臓
ISBN： 9784865170924
電子書籍版： 2014-12-10
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,860 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,430 円(税込)

購入する

商品紹介

シリーズ第18弾！　透析医療における臨床研究の意義と題し、透析医療における観察研究の意義を分かり易く解説した特集を収載しています。

目次

  • 透析療法ネクスト　XVIII

    ―目次―

    座談会
    ■臨床医からみた今後の臨床研究の在り方
    　〜透析医療の更なる進展に向けて〜

    特集　透析医療における臨床研究の意義
    ■1．透析医療と臨床研究
    　　1）臨床研究を取り巻く環境の変化
    　　2）臨床研究の分類と特徴
    　　3）透析医療になぜ臨床研究が必要とされるのか
    ■2．透析医療における観察研究
    　　1）DOPPS
    　　2）MBD-5D 研究
    ■ 3．透析医療における介入研究
    　　1）代表的な介入研究（RCT）
    　　2）介入研究と観察研究のギャップをどう考えるか
    ■ 4．今後の課題
    　　1）臨床研究におけるビッグデータの活用と意義
    　　2）臨床研究に求められる倫理性

    ■透析療法の歴史（18）　薬物療法の変遷・進歩の歴史
    はじめに
    窒素代謝産物に関する薬物療法
    高尿酸血症に対する薬物療法
    脂質代謝異常に対する薬物療法
    体液量過剰、浮腫に対する薬物療法
    高カリウム血症と代謝性アシドーシスに対する薬物療法
    CKD-MBD に対する薬物療法
    QOL やADL を阻害する病態に対する薬物療法
    レストレス症候群（restless legs syndrome：RLS）に対する薬物療法
    神経・筋肉異常・筋痙攣などに対する薬物療法
    透析掻痒症（dialysis itching）に対する薬物療法

    ■INDEX

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

座談会

P.8 掲載の参考文献
1) Held PJ et al : Am J Kidney Dis 15 (5), 451-457, 1990
PubMed
2) Pisoni RL et al : Am J Kidney Dis 53 (3), 475-491, 2009
PubMed
3) Pisoni RL et al : Am J Kidney Dis 44 (1), 94-111, 2004
PubMed
4) Concato J et al : N Engl J Med 342 (25), 1887-1892, 2000
PubMed
5) Moe S et al : Kidney jnt 69 (11), 1945-1953, 2006
 
6) Kidney Disease : Improving Global Outcomes (KDIGO) CKD-MBD Work Group : Kidney Int 76 (Suppl 113), S1-130, 2009
 
7) 日本透析医学会 : 透析会誌 39 (10), 1435-1455, 2006
 
8) Hanafusa N et al : Nephrol Dial Transplant 2014, Epub ahead of print
 
9) Archdeacon P et al : Clin J Am Soc Nephrol 8 (9), 1609-1617, 2013
PubMed
10) 公益法人ヒューマンサイエンス振興財団 : 平成25年度 (2013年度) 将来動向調査報告書「慢性腎臓病 (CKD) の将来動向 II」【分析編】2013
 
11) Roscioni SS et al : Kidney Int 86 (1), 40-49, 2014
PubMed
12) Maclsaac RJ et al : Kidney Int 86 (1), 50-57, 2014
 
13) National Kidney Foundation : http://www.kidney.org/news/newsroom/nr/Earlier-Endpoints-Proposed-for-Clinical-Trials-in-CKD
 
14) Coresh J et al : JAMA 311 (24), 2518-2531, 2014
PubMed
15) EUROPEAN MEDICINES AGENCY : EMA/CHMP/355988/2014
 
16) Pergola PE et al : N Engl J Med 365 (4), 327-336, 2011
PubMed
17) de Zeeuw D et al : N Engl J Med 369 (26), 2492-2503, 2013
PubMed

特集 透析医療における臨床研究の意義

P.17 掲載の参考文献
1) Strippoli GF, Craig JC, Schena FP : The Number, Quality, and Coverage of Randomized Controlled Trials in Nephrology. J Am Soc Nephrol 15 : 411-419, 2004
PubMed
2) Archdeacon P, Shaffer RN, Winkelmayer WC, et al : Fostering Innovation, Advancing Patient Safety : The Kidney Health Initiative. Clin J Am Soc Nephrol 8 : 1609-1617, 2013
PubMed
3) 総合科学技術会議「科学技術の振興及び成果の社会への還元に向けた制度改革について (案)」. 平成18年12月25日. http://www8.cao.go.jp/cstp/siryo/haihu62/siryo1-2.pdf
 
4) 厚生労働省 : 臨床研究中核病院整備事業の公募結果. 平成25年4月19日. http://www.mhlw.gojp/stf/houdou/2r985200000304vd.html
 
5) 辰巳邦彦 : 主要基礎・臨床医学論文掲載数の国際比較. 政策研ニュース 35 : 48-49, 2012
 
6) 高鳥登志郎 : わが国における臨床医学研究の現状と国際比較. 政策研ニュース 25 : 18-23, 2008
 
7) 厚生労働省 : 臨床研究に係る制度の見直しの方向性について. 第7回臨床研究に係る制度の在り方に関する検討会. 平成26年10月22日. http://www.mhlw.go.jp/file/05-Shingikai-10801000-lseikyoku-Soumuka/0000062005.pdf
 
8) McMahon AD, Conway DI, Macdonald TM, et al : The unintended consequences of clinical trials regulations. PLoS Med 3 (11) : e1000131, 2009. doi : 10. 1371/journal. pmed. 1000131. Epub 2009 Nov 17.
 
P.30 掲載の参考文献
1) 福原俊一 : 臨床研究の道標. 2013. 健康医療評価研究機構. http://www.i-hope.jp.
 
2) Dowd R, Recker RR, Heaney RP : Study subjects and ordinary patients. Osteoporos Int 11 : 533-536, 2000
PubMed
3) Concato J, Shah N, Horwitz RI : Randomized, controlled trials, observational studies, and the hierarchy of research designs. New Engl J Med 342 : 1887-1892, 2000
PubMed
4) Dahabreh IJ, Kent DM : Can the learning health care system be educated with observational data? JAMA 312 : 129-130, 2014
PubMed
5) Saran R, Brag9-Gresham JL, Levin NW, et al : Longer treatment time and slower ultrafiltration in hemodialysis : associations with reduced mortality in the DOPPS. Kidney Int 69 : 1222-1228, 2006
 
6) Cziraky MJ, Willey VJ, McKenney JM, et al : Statin safety : an assessment using an administrative claims database. Am J Caridol 97 : 61C-68C, 2006
 
P.34 掲載の参考文献
1) 福原俊一 : 臨床研究の道標 (みちしるべ) -7つのステップで学ぶ研究デザイン. 京都 : 特定非営利活動法人健康医療評価研究機構, 2013
 
2) Bazeley J, Bieber B, Li Y, et al : C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients. Clin J Am Soc Nephro16 : 2452-2461, 2011
 
3) Nishizawa Y, Shoji T, Maekawa K, et al : Intima-media thickness of carotid artery predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 41 : S76-79, 2003
PubMed
4) Shoji T, Emoto M, Shinohara K, et al : Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 12 : 2117-2124, 2001
PubMed
5) Liu Y, Coresh J, Eustace JA, et al : Association between cholesterol level and mortality in dialysis patients : role of inflammation and malnutrition. JAMA 291 : 451-459, 2004
 
6) Wanner C, Krane V, Marz W, et al : Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 : 238-248, 2005
PubMed
7) Fellstrom BC, Jardine AG, Schmieder RE, et al : Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360 : 1395-1407, 2009
PubMed
8) Baigent C, Landray MJ, Reith C, et al : The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection) : a randomised placebocontrolled trial. Lancet 377 : 2181-2192, 2011
PubMed
9) Shoji T, Shinohara K, Kimoto E, et al : Lower risk for cardiovascular mortality in oral lalpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 19 : 179-184, 2004
 
P.41 掲載の参考文献
1) http://www.doppsorg/DOPPS/AbOuttheDOPPS.aspx
 
P.48 掲載の参考文献
1) Vanholder RC, Ringoir SM : Adequacy of dialysis : a critical analysis. Kidney Int 42 : 540-558, 1992
PubMed
2) 血液透析処方ガイドライン作成ワーキンググループ. 透析会誌 46 : 587-632, 2013
 
3) Barth RH : Urea modeling and Kt/V : a critical appraisal. Kidney Int 43 (Suppl 41) : 60 : S252-260, 1993
 
4) Lowrie EG, Laird NM, Parker TF, et al : Effect of the hemodialysis prescription of patient morbidity : report from the National Cooperative Dialysis Study. N Engl J Med 305 : 1176-1181, 1981
PubMed
5) Gotch FA, Sargent JA : Amechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 28 : 526-534, 1985
 
6) Kimata N, Karaboyas A, Bieber BA, et al : Gender, low Kt/V, and mortality in Japanese hemodialysis patients : opportunities for improvement through modifiable practices. Hemodial Int 18 : 596-606, 2014
 
7) Owen WF Jr, Lew NL, Liu Y, et al : The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329 : 1001-1006, 1993
PubMed
8) Held PJ, Port FK, Wolfe RA, et al : The dose of hemodialysis and patient mortality. Kidney Int 50 : 550-556, 1996
PubMed
9) Eknoyan G, Beck GJ, Cheung AK, et al : Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347 : 2010-2019, 2002
 
10) Saran R, Bragg-Gresham JL, Levin NW, et al : Longer treatment time and slower ultrafiltration in hemodialysis : associations with reduced mortality in the DOPPS. Kidney Int 69 : 1222-1228, 2006
PubMed
11) Shinzato T, Nakai S, Akiba T, et al : Survival in long-term haemodialysis patients : results from the annual survey of the Japanese Society for Dialysis Therapy. Nephrol Dial Transplant 12 : 884-888, 1997
PubMed
12) 鈴木一之, 井関邦敏, 中井滋, 他 : 血液透析条件・透析量と生命予後-日本透析医学会の統計調査結果から-. 透析会誌 43 : 551-559, 2010
 
13) Port FK, Wolfe RA, Hulbert-Shearon TE, et al : High dialysis dose is associated with lower mortality among women but not among men. Am J Kidney Dis 43 : 1014-1023, 2004
 
14) Tentori F, Zhang J, Li Y, et al : Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis : results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 27 : 4180-4288, 2012
 
P.61 掲載の参考文献
1) Young EW, Goodkin DA, Mapes DL, et al : The Dialysis Outcomes and Practice Patterns Study (DOPPS) : An international hemodialysis study. Kidney Int 74 : S74-81, 2000
 
2) Pisoni RL, Gillespie BW, Dickinson DM, et al : The Dialysis Outcomes and Practice Patterns Study (DOPPS) : design, data elements, and methodology. Am J Kidney Dis 44 : 7-15, 2004
PubMed
3) Johansen KL, Finkelstein FO, Revicki DA, et al : Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients. Nephrol Dial Transplant 27 : 2418-2425, 2012
PubMed
4) Kalantar-Zadeh K, KoPPle JD, Block G, et al : Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. J Am Soc Nephrol 12 : 2797-2806, 2001
PubMed
5) Pascual J, Teruel JL, Moya JL, et al : Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis : a prospective study. Clin Nephrol 35 : 280-287, 1991
PubMed
6) Besarab A, Bolton WK, Browne JK, et al : The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 : 584-590, 1998
PubMed
7) Pisoni RL, Brag9-Gresham JL, Young EW, et al : Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44 : 94-111, 2004
 
8) Locatelli F, Pisoni RL, Combe C, et al : Anaemia in haemodialysis patients of five European countries : association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19 : 121-132, 2004
 
9) Akizawa T, Pisoni RL, Akiba T, et al : Japanese haemodialysis anaemia management practices and outcomes (1999-2006) : results from the DOPPS. Nephrol Dial Transplant 23 : 3643-3653, 2008
PubMed
10) Goodkin DA, Fuller DS, Robinson BM, et al : Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. J Am Soc Nephrol 22 : 358-365, 2011
 
11) Inaba M, Hayashino Y, Shoji T, et al : Disappearance of Association in Diabetic Patients on Hemodialysis between Anemia and Mortality Risk : The Japan Dialysis Outcomes and Practice Pattern Study. Nephron Clin Pract 120 : c91-c100, 2012
PubMed
12) Hanafusa N, Nomura T, Hasegawa T, et al : Age and anemia management : relationship of hemoglobin levels with mortality might differ between elderly and nonelderly hemodialysis patients. Nephrol Dial Transplant, 2014
PubMed
13) Fishbane S, Berns JS : Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 68 : 1337-1343, 2005
PubMed
14) Pisoni RL, Bragg-Gresham JL, Fuller DS, et al : Facility-level interpatient hemoglobin variability in hemodialysis centers participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS) : Associations with mortality, patient characteristics, and facility practices. Am J Kidney Dis 57 : 266-275, 2011
PubMed
15) Locatelli F, Pisoni RL, Akizawa T, et al : Anemia management for hemodialysis patients : Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings. Am J Kidney Dis 44 : 27-33, 2004
PubMed
16) McFarlane PA, Pisoni RL, Eichleay MA, et al : International trends in erythropoietin use and hemoglobin levels in hemodialysis patients. Kidney Int 78 : 215-223, 2010
PubMed
17) Singh AK, Szczech L, Tang KL, et al : Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 : 2085-2098, 2006
PubMed
18) Drueke TB, Locatelli F, Clyne N, et al : Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 : 2071-2084, 2006
PubMed
19) Pfeffer MA, Burdmann EA, Chen CY, et al : A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361 : 2019-2032, 2009
PubMed
20) US-DOPPS Practice Monitor. http://www.dopps.org/DPM.
 
21) KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kindey Int 2 : S279-335, 2012
 
22) Bailie GR, Larkina M, Goodkin DA, et al : Variation in intravenous iron use internationally and over time : the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 28 : 2570-2579, 2013
PubMed
23) Fukuma S, Yamaguchi T, Hashimoto S, et al : Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients : results from a cohort study from the dialysis registry in Japan. Am J Kidney Dis 59 : 108-116, 2012
PubMed
24) Fujikawa T, Ikeda Y, Fukuhara S, et al : Time-dependent resistance to erythropoiesis-stimulating agent and mortality in hemodialysis patients in the Japan Dialysis Outcomes and Practice Patterns Study. Nephron Clin Pract 122 : 24-32, 2012
PubMed
25) Yokoyama H, Kawaguchi T, Wada T, et al : Biocompatibility and permeability of dialyzer membranes do not affect anemia, erythropoietin dosage or mortality in japanese patients on chronic non-reuse hemodialysis : a prospective cohort study from the JDOPPS II study. Nephron Clin Pract 109 : c100-108, 2008
 
26) Kimata N, Akiba T, Pisoni RL, et al : Mineral metabolism and haemoglobin concentration among haemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 20 : 927-935, 2005
PubMed
27) Hasegawa T, Bragg-Gresham JL, Pisoni RL, et al : Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin. Kidney Int 79 : 340-346, 2011
PubMed
P.71 掲載の参考文献
1) Tentori F, Fuller DS, Port FK, et al : The DOPPS practice monitor for US dialysis care : potential impact of recent guidelines and regulatory changes on management of mineral and bone disorder among US hemodialysis patients. Am J Kidney Dis 63 : 851-854, 2014
PubMed
2) Tentori F, Blayney MJ, Albert JM, et al : Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH : the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52 : 519-530, 2008
PubMed
3) Blayney MJ, Pisoni RL, Brag9-Gresham JL, et al : High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int 74 : 655-663, 2008
 
4) Jadoul M, Albert JM, Akiba T, et al : Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70 : 1358-1366, 2006
PubMed
5) Tanaka M, Yamazaki S, Hayashino Y, et al : Hypercalcaemia is associated with poor mental health in haemodialysis patients : results from Japan DOPPS. Nephrol Dial Transplant 22 : 1658-1664, 2007
PubMed
6) Kimata N, Akiba T, Pisoni RL, et al : Mineral metabolism and haemoglobin concentration among haemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 20 : 927-935, 2005
PubMed
7) Tonelli M, Blake PG, Muirhead N : Predictors of erythropoietin responsiveness in chronic hemodialysis patients. ASAIO J 47 : 82-85, 2001
PubMed
8) Tentori F, Albert JM, Young EW, et al : The survival advantage for haemodialysis patients taking vitamin D is questioned : findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 24 : 963-972, 2009
PubMed
9) Lopes AA, Tong L, Thumma J, et al : Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS) : evaluation of possible confounding by nutritional status. Am J Kidney Dis 60 : 90-101, 2012
PubMed
10) Tentori F, McCullough K, Kilpatrick RD, et al : High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int 85 : 166-173, 2014
PubMed
P.82 掲載の参考文献
1) Fissell RB, Fuller DS, Morgenstern H, et al : Hemodialysis Patient Preference for Type of Vascular Access : Variation and Predictors Across Countries in the DOPPS. J Vasc Access 14 : 264-272, 2013
PubMed
2) Asano M, Thumma JR, Oguchi K, et al : Vascular access care and treatment practices associated with outcomes of arteriovenous fistula : International comparisons from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephron Clin Pract 124 : 23-30, 2013
 
3) Robinson BM, Fuller DS, Zinsser D, et al : The Dialysis Outcomes and Practice Patterns Study (DOPPS) Practice Monitor : Rationale and methods for an initiative to monitor the new US bundled dialysis payment system. Am J Kidney Dis 57 : 822-831, 2011
 
4) Ng LJ, Chen F, Pisoni RL, et al : Hospitalization risks related to vascular access type among incident US hemodialysis patients. Nephrol Dial Transplant 26 : 3659-3666, 2011
PubMed
5) Wikstrom B, Jacobson SH, Bragg-Gresham JL, et al : DOPPS Estimate of Patient Life Years Attributable to Modifiable Hemodialysis Practices in Sweden. Nephrol Dial Transplant 27 : 4464-4472, 2012
 
6) Robinson BM, Port FK : Caring for Dialysis Patients : International insights from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Semin Dial 23 : 4-6, 2010
PubMed
7) Rayner HC, Pisoni RL : The increasing use of hemodialysis catheters : evidence from the DOPPS on its significance and ways to reverse it. Semin Dial 23 : 6-10, 2010
PubMed
8) Goodkin DA, Pisoni RL, Locatelli F, et al : Hemodialysis vascular access training and practices are key to improved access outcomes. Am J Kidney Dis 56 : 1032-1042, 2010
PubMed
9) Pisoni RL, Arrington CJ, Albert JM, et al : Facility hemodialysis vascular access use and mortality in countries participating in DOPPS : An instrumental variable analysis. Am J Kidney Dis 53 : 475-491, 2009
PubMed
10) Bradbury BD, Chen F, Furniss AL, et al : Conversion of vascular access type among incident hemodialysis patients : Description and association with mortality. Am J Kidney Dis 53 : 804-814, 2009
 
11) Combe C, Albert JM, Bragg-Gresham JL, et al : The burden of amputation among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Am J Kidney Dis 54 : 680-692, 2009
PubMed
12) Saran R, Elder SJ, Goodkin DA, et al : Enhanced Training in Vascular Access Creation Predicts Arteriovenous Fistula Placement and Patency in Hemodialysis Patients : Results From the Dialysis Outcomes and Practice Patterns Study. Ann Surg 247 : 885-891, 2008
PubMed
13) Canaud B, Combe CH, Brag9-Gresham JL, et al : DOPPS estimate of patient life years attributable to modifiable hemodialysis practices in France. Nephrol Ther 4 : 256-265, 2008
 
14) Ethier J, Mendelssohn DC, Elder SJ, et al : Vascular access use and outcomes : an international perspective : results from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 23 : 4088, 2008
 
15) Bradbury BD, Fissell RB, Albert JM, et al : Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol 2 : 89-99, 2007
PubMed
16) Nicholson T, Roderick P : International Study of Health Care Organization and Financing of renal services in England and Wales. Int J Health Care Finance Econ 7 : 283-299, 2007
 
17) Pontoriero G, Locatelli F, Andreucci VE, et al : Stima DOPPS dell! impatto delle linee guida sulla sopravvivenza in emodialisi in Italia. G Ital Nefrol 24 : 221-229, 2007
 
18) Mendelssohn DC, Ethier J, Elder SJ, et al : Hemodialysis vascular access problems in Canada : Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS II). Nephrol Dial Transplant 21 : 721-728, 2006
PubMed
19) Port FK, Pisoni RL, Bommer J, et al : Improving Outcomes for Dialysis Patients in the International Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol 1 : 246-255, 2006
PubMed
20) Pisoni RL, Greenwood RN : Selected lessons learned from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Contrib Nephrol 149 : 58-68, 2005
PubMed
21) Saran R, Dykstra DM, Pisoni RL, et al : Timing of first cannulation and vascular access failure in haemodialysis : An analysis of practice patterns at dialysis facilities in the DOPPS. Nephrol Dial Transplant 19 : 2334-2340, 2004
 
22) Pisoni RL, Gillespie BW, Dickinson DM, et al : The Dialysis Outcomes and Practice Patterns Study : Design, Data Elements, and Methodology. Am J Kidney Dis 44 (5 Suppl 2) : 7-15, 2004
 
23) Rayner HC, Besarab A, Brown W, et al : Vascular Access Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS) : Performance Against Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines. Am J Kidney Dis 44 (5 Suppl 2) : 22-26, 2004
 
24) Andreucci VE, Fissell RB, Bragg-Gresham JL, et al : DOPPS Data on Medications in Hemodialysis Patients. Am J Kidney Dis 44 (5 Suppl 2) : 61-67, 2004
 
25) Rayner HC, Pisoni RL, Bommer J, et al : Mortality and hospitalisation in haemodialysis patients in five European countries : results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19 : 108-120, 2004
 
26) Port FK, Pisoni RL, Brag9-Gresham JL, et al : DOPPS Estimates of Patient Life Years Attributable to Modifiable Hemodialysis Practices in the United States. Blood Purif 22 : 175-180, 2004
 
27) Saran R, Pisoni RL, Weitzel W : Epidemiology of vascular access for hemodialysis and related practice patterns. Contrib Nephrol 142 : 14-28, 2004
PubMed
28) Pisoni RL, Young EW, Mapes DL, et al : Vascular access use and outcomes in the US., Europe, and Japan : Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol News Issues 17 : 38-43, 47, 2003
 
29) Rayner HC, Pisoni RL, Gillespie BW, et al : Creation, cannulation and survival of arterio-venous fistulae-data from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 63 : 323-330, 2003
 
30) Young EW, Dykstra DM, Goodkin DA, et al : Hemodialysis vascular access preferences and outcomes in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 61 : 2266-2271, 2002
PubMed
31) Pisoni RL, Young EW, Dykstra DM, et al : Vascular access use in Europe and the United States : results from the DOPPS. Kidney Int 61 : 305-316, 2002
PubMed
32) Saran R, Dykstra DM, Wolfe RA, et al : Association between vascular access failure and the use of specific drugs : the Dialysis Outcomes and Practice Patterns Study (DOPPS), Am J Kidney Dis 40 : 1255-1263, 2002
PubMed
33) Pisoni RL : Vascular access use and outcomes : results from the DOPPS. Contrib Nephrol 137 : 13-19, 2002
PubMed
34) Combe CH, Pisoni RL, Port FK, et al : Dialysis Outcomes and Practice Patterns Study : donnges sur lutilisation des catheters veineux centraux en h6modialyse chroniqu. Nephrologie 22 : 379-384, 2001
 
35) Goodkin DA, Mapes DL, Held PJ : The Dialysis Outcomes and Practice Patterns Study (DOPPS) : How can we improve the care of hemodialysis patients? Semin Dial 14 : 157-159, 2001
PubMed
36) Young EW, Goodkin DA, Mapes DL, et al : The Dialysis Outcomes and Practice Patterns Study (DOPPS) : an international hemodialysis study. Kidney Int 57 (Suppl 74) : S74-S81, 2000
 
37) Ravani P, Gillespie BW, Quinn RR, et al : Temporal risk profile for infectious and noninfectious complications of hemodialysis access. J Am Soc Nephrol 24 : 1668-1677, 2013
PubMed
38) Robinson BM, Bieber B, Pisoni RL, et al : Dialysis Outcomes and Practice Patterns Study (DOPPS) : its strengths, limitations, and role in informing practices and policies. Clin J Am Soc Nephrol 7 : 1897-1905, 2012
PubMed
39) Perl J, Zhang J, Gillespie B, et al : Reduced survival and quality of life following return to dialysis after transplant failure : the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 27 : 4464-4472, 2012
PubMed
40) Yeates KE, Mendelssohn DC, Ethier J, et al : Optimizing hemodialysis practices in Canada could improve patient survival. CANNT J 17 : 22-34, 2007
PubMed
41) Mendelssohn DC, Yeates KE, Ethier J, et al : DOPPS estimate of patient life years attributable to modifiable hemodialysis practices in Canada. Nephrol News Issues 21 : 69-70, 72, 74-6 passim, 2007
 
42) Pontoriero G, Santoro D, Messina A, et al : The Dialysis Outcomes and Practice Patterns Study (DOPPS) : results of the Italian cohort. G Ital Nefrol 22 : 494-502, 2005
PubMed
43) Cruz JM, Piera L, Bragg-Gresham JL, et al : Results of the international hemodialysis study DOPPS in Spain and Europe. Nefrologia 23 : 437-443, 2003
PubMed
44) Hasegawa T, Elder SJ, Brag9-Gresham JL, et al : Consistent aspirin use associated with improved arteriovenous fistula survival among incident hemodialysis patients in the dialysis out comes and practice patterns study. Clin J Am Soc Nephrol 3 : 1373-1378, 2008
 
P.96 掲載の参考文献
1) Moe S, Drueke T, Cunningham J, et al : Definition, evaluation, and classification of renal osteodystrophy : a position statement from Kidney Disease : Improving Global Outcomes (KDIGO). Kidney Int 69 : 1945-1953, 2006
PubMed
2) 深川雅史, 平方秀樹, 秋澤忠男, 他 : 透析患者における二次性副甲状腺機能亢進症治療ガイドライン. 透析会誌 39 : 1435-1455, 2006
 
3) Guideline Working Group, Japanese Society for Dialysis Therapy : Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 12 : 514-525, 2008
 
4) 秋澤忠男, 平方秀樹, 友雅司, 他 : 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 透析会誌 45 : 301-356, 2012
 
5) Fukagawa M, Yokoyama K, Koiwa F, et al : Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial 17 : 247-288, 2013
PubMed
6) Fukuhara S, Akizawa T, Fukagawa M, et al : Mineral and bone disorders outcomes study for Japanese chronic kidney disease stage 5D patients : rationale and study design. Ther Apher Dial 15 : 169-175, 2011
PubMed
7) Goodkin DA, Brag9-Gresham JL, Koenig KG, et al : Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States : the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 14 : 3270-3277, 2003
 
P.107 掲載の参考文献
1) National Kidney Foundation : K/DOQI Clinical Practice Guidelines. Am J Kidney Dis 42 (Suppl 3) : S1-S202, 2003
 
2) 日本透析医学会 : 透析患者における二次性副甲状腺機能亢進症治療ガイドライン. 透析会誌 39 : 1435-1455, 2006
 
3) KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 76 (Suppl 113) : S1-130, 2009
 
4) 日本透析医学会ワーキンググループ : 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 透析会誌 45 : 301-356, 2012
 
5) Raggi P, Chertow GM, Torres PU, et al : ADVANCE study : A randomized vascular calcification study to evaluate the effect of Cinacalcet Plus low. does Vitamin D on Vascular Calcification in Patients on hemodialysis. Nephrol Dial Transplant 26 : 1327-1339, 2011
 
6) Parfrey PS, Chertow GM, Block GA, et al : The Clinical Course of Treated Hyperparathyroidism Among Patients Receiving Hemodialysis and the Effect of Cinacalcet : The EVOLVE Trial. J Clin Endocrinol Metab 98 : 4834-4844, 2013
 
7) Fukagawa M, Yumita S, Akizawa T, et al : Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 23 : 328-335, 2008
PubMed
8) Komaba H, Nakanishi S, Fujimori A, et al : Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol 5 : 2305-2314, 2010
 
9) Blacher J, Guerin AP, Pannier B, et al : Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stagerenal disease. Hypertension 38 : 938-942, 2001
 
10) Fukagawa M, Komaba H, Onishi Y, et al : A Mineral Metabolism Management in Hemodialysis Patients with Secondary Hyperparathyroidism in Japan : Baseline Data from the MBD-5D. Am J Nephrol 33 : 427-437, 2011
PubMed
11) Fukagawa M, Fukuma S, Onishi Y, et al : Prescription Patterns and Mineral Metabolism Abnormalities in the Cinacalcet Era : Results from the MBD-5D Study. Clin J Am Soc Nephrol 7 : 1473-1480, 2012
PubMed
12) Fukagawa M, Kido R, Komaba H, et al : Abnormal Mineral Metabolism and Mortality in Hemodialysis Patients With Secondary Hyperparathyroidism : Evidence From Marginal Structural Models Used to Adjust for Time-Dependent Confounding. Am J Kidney Dis 63 : 979-987, 2014
PubMed
13) Block GA, Hulbert-Shearon TE, Levin NW, et al : Association of serum phosphorus and calcium×phosphate product with mortalityrisk in chronic hemodialysis patients : a national study. Am J Kidney Dis 31 : 607-617, 1998
 
14) Block GA, Klassen PS, Lazarus JM, et al : Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15 : 2208-2218, 2004
PubMed
15) Young EW, Akiba T, Albert JM, et al : Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44 (Suppl 2) : 34-38, 2004
PubMed
16) Moe S, Drueke T, Cunningham J, et al : Definition, evaluation, and classification of renal osteodystrophy : A position statement from Kidney Disease : Improving Global Outcomes (KDIGO). Kidney Int 69 : 1945-1953, 2006
PubMed
17) Noordzij M, Cranenburg EM, Engelsman LF, et al : Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients. Nephrol Dial Transplant 26 : 1662-1669, 2011
 
18) Taniguchi M, Fukagawa M, Fujii N, et al : Serum Phosphate and Calcium Should Be Primarily and Consistently Controlled in Prevalent Hemodialysis Patients. Ther Apher Dial 17 : 221-228, 2013
PubMed
19) Floege J, Kim J, Ireland E, et al : Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 26 : 1948-1955, 2011
 
P.115 掲載の参考文献
1) Wanner C, Krane V, Marz W, et al : Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 : 238-248, 2005
PubMed
2) Fellstrom BC, Jardine AG, Schmieder RE, et al : Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360 : 1395-1407, 2009
PubMed
3) Baigent C, Landray MJ, Reith C, et al : The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection) : a randomised placebocontrolled trial. Lancet 377 : 2181-2192, 2011
PubMed
4) Marz W, Genser B, Drechsler C, et al : Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol 6 : 1316-1325, 2011
PubMed
5) Block GA, Spiegel DM, Ehrlich J, et al : Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68 : 1815-1824, 2005
PubMed
6) Suki WN, Zabaneh R, Cangiano JL, et al : Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72 : 1130-1137, 2007
PubMed
7) EVOLVE Trial Investigators : Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367 : 2482-2494, 2012
PubMed
P.124 掲載の参考文献
1) McMahon LP, McKenna MJ, Sangkabutra T, et al : Physical performance and associated electrolyte changes after haemoglobin normalization : a comparative study in haemodialysis patients. Nephrol Dial Transplant 14 : 1182-1187, 1999
PubMed
2) Levin A, Thompson CR, Ethier J, et al : Left ventricular mass index increase in early renal disease : impact of decline in hemoglobin. Am J Kidney Dis 34 : 125-134, 1999
PubMed
3) Pickett JL, Theberge DC, Brown WS, et al : Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 33 : 1122-1130, 1999
PubMed
4) Besarab A, Amin N, Ahsan M, et al : Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11 : 530-538, 2000
PubMed
5) Collins A, Ma J, Umen A : Hematocrit as a time-dependent risk factor. J Am Soc Nephrol 439, 1994
 
6) Pisoni RL, Bragg-Gresham JL, Young EW, et al : Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44 : 94-111, 2004
PubMed
7) Isakova T, Gutierrez OM, Chang Y, et al : Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 20 : 388-396, 2009
 
8) Pisoni RL, Bragg-Gresham JL, Fuller DS, et al : Facility-level interpatient hemoglobin variability in hemodialysis centers participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS) : Associations with mortality, patient characteristics, and facility practices. Am J Kidney Dis 57 : 266-275, 2011
PubMed
9) Kalantar-Zadeh K, Regidor DL, McAllister CJ, et al : Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16 : 3070-3080, 2005
PubMed
10) Feldman HI, Santanna J, Guo W, et al : Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 13 : 734-744, 2002
PubMed
11) Feldman HI, Joffe M, Robinson B, et al : Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 15 : 1623-1632, 2004
PubMed
12) Kalantar-Zadeh K, Hoffken B, Wunsch H, et al : Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 26 : 292-299, 1995
 
13) Hussein S, Prieto J, O'Shea M, et al : Serum ferritin assay and iron status in chronic renal failure and haemodialysis. Br Med J 1 : 546-548, 1975
 
14) Mirahmadi KS, Paul WL, Winer RL, et al : Serum ferritin level. Determinant of iron requirement in hemodialysis patients. JAMA 238 : 601-603, 1977
PubMed
15) Aljama P, Ward MK, Pierides AM, et al : Serum ferritin concentration : a reliable guide to iron overload in uremic and hemodialyzed patients. Clin Nephrol 10 : 101-104, 1978
PubMed
16) Hasuike Y, Nonoguchi H, Tokuyama M, et al : Serum ferritin predicts prognosis in hemodialysis patients : the Nishinomiya study. Clin Exp Nephrol 14 : 349-355, 2010
PubMed
P.130 掲載の参考文献
1) 厚生労働科学研究指定研究 : 「我が国の医療資源の必要量の定量とその適正な配分から見た医療評価のあり方に関する研究 (H25-政策-指定-010, 研究代表者 伏見清秀)」総括・分担研究報告書. 2014年3月.
 
2) 康永秀生, 堀口裕正 : 大規模標準化診療データと臨床疫学研究. 松田晋哉, 伏見清秀編著 : 診療情報による医療評価. 東京大学出版会. 東京. 2012年9月.
 
P.138 掲載の参考文献
1) 世界医師会, 日本医師会訳 : 人間を対象とする医学研究の倫理的原則 (ヘルシンキ宣言) 2013.
 
2) 厚生労働省 : 疫学研究に関する倫理指針 2008.
 
3) 厚生労働省 : 臨床研究に関する倫理指針 2008.
 
4) 厚生労働省 : 人を対象とする医学系研究に対する倫理指針 (案) 2014.
 

透析療法の歴史 ( 18 ) 薬物療法の変遷・進歩の歴史

P.150 掲載の参考文献
1) 秋澤忠男, 他 : 大規模臨床試験の成果-日常診療へのインパクト (8) クレメジン. 腎臓 36 : 215-219, 2014
 

書評

最近チェックした商品履歴

Loading...